KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Abbott Laboratories (ABT) Accumulated Depreciation & Amortization (2016 - 2025)

Abbott Laboratories' Accumulated Depreciation & Amortization history spans 17 years, with the latest figure at $13.4 billion for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 10.96% year-over-year to $13.4 billion; the TTM value through Dec 2025 reached $13.4 billion, up 10.96%, while the annual FY2025 figure was $13.4 billion, 10.96% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $13.4 billion at Abbott Laboratories, up from $13.3 billion in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $13.4 billion in Q4 2025 and bottomed at $9.9 billion in Q1 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $11.5 billion (2023), against an average of $11.5 billion.
  • The largest annual shift saw Accumulated Depreciation & Amortization increased 13.59% in 2021 before it grew 2.57% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $10.4 billion in 2021, then rose by 6.2% to $11.0 billion in 2022, then rose by 6.6% to $11.8 billion in 2023, then grew by 2.57% to $12.1 billion in 2024, then rose by 10.96% to $13.4 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Accumulated Depreciation & Amortization are $13.4 billion (Q4 2025), $13.3 billion (Q3 2025), and $13.1 billion (Q2 2025).